Rawa K. Ismail

University of Leicester — United Kingdom

Medicine · Health Sciences

10h-index316citations32works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous Melanoma Detection and Management(10), Cancer Immunotherapy and Biomarkers(8), CAR-T cell therapy research(7), Melanoma and MAPK Pathways(6), Cancer Genomics and Diagnostics(4)

Publications32 total

National assessments in verse
Science·2025
Comprehensive Literature Review on the Use of Heart Rate Variability as a Biomarker for Concussion Recovery (P5-4.007)
Neurology·2025
28 Comparison of Genetic Alteration Concordance Rates: Liquid biopsy vs Conventional biopsy in Non-Small Cell Lung Cancer
Lung Cancer·2025
22 Challenges in Meeting Molecular Testing Turnaround Times in Lung Cancer
Lung Cancer·2025
LIMITATIONS OF PET SCAN IN THE DETECTION OF DISTAL METASTASES OF BRONCHOPULMONARY CANCER
International Journal of Advanced Research·2024Open Access
Abstract 367: Physiologic steal in white matter structures of non‐flow limited cerebral hemispheres as evidenced by observations of acetazolamide challenge arterial spin labeling MR
Stroke Vascular and Interventional Neurology·2024Open Access
Abstract 331: MR Steal Phenomenon Corresponds to Cerebral Angiogram Circulation Time
Stroke Vascular and Interventional Neurology·2024Open Access
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
EClinicalMedicine·2024· 20 citedOpen Access
A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors
Cancers·2023· 4 citedOpen Access
Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC
BMC Medical Research Methodology·2023Open Access
Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC
BMC Medical Research Methodology·2023· 9 citedOpen Access
End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study
JCO Oncology Practice·2022· 4 citedOpen Access
Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis
Journal of Medical Internet Research·2022· 2 citedOpen Access
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
Melanoma Research·2022· 26 citedOpen Access
Real-world data in cancer treatment
2022Open Access
Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study
European Journal of Cancer·2022· 56 citedOpen Access
Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
The Breast·2022· 1 citedOpen Access
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
The Breast·2021· 40 citedOpen Access
The unfavorable effects of <scp>COVID</scp>‐19 on Dutch advanced melanoma care
International Journal of Cancer·2021· 22 citedOpen Access
Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis (Preprint)
2021
page 1 of 2Next →

Frequent Co-authors

Michel W.J.M. Wouters(21), Doranne L. Hilarius(16), John B.A.G. Haanen(14), Maureen J.B. Aarts(14), Geke A.P. Hospers(14), Ellen Kapiteijn(14), Djura Piersma(14), Karijn P.M. Suijkerbuijk(14), Maaike van Dartel(14), Astrid A.M. van der Veldt(12), Marye J. Boers‐Sonderen(11), Anthonius de Boer(11), Jesper van Breeschoten(10), Gerard Vreugdenhil(10), Christian U. Blank(9), Franchette W.P.J. van den Berkmortel(9), Jan Willem B. de Groot(9), Anna M.G. Pasmooij(8), Willeke A.M. Blokx(7), Melissa M. de Meza(6)